Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

DNA2.0, VTU Partner on Proteins

By Drug Discovery Trends Editor | September 24, 2012

DNA2.0, the leading bioengineering solutions provider, and VTU Technology, the leader in Pichia pastoris protein expression services, announced a partnership to develop and refine a gene design algorithm to enable maximized protein production in the yeast P. pastoris. The collaboration will combine VTU´s deep P. pastoris expertise and AOX1 promoter technology with DNA2.0’s gene design technology for robust translation.

“Pichia is ideally suited for high-level expression of recombinant proteins for therapeutic and industrial applications,” said Dr. Thomas Purkarthofer, Head of Business Development of VTU Technology. “We are excited to merge the unparalleled strength of our P. pastoris expression system with DNA2.0’s industry-leading gene design and expression optimization technology.”

VTU’s P. pastoris protein expression platform is based on engineered versions of the AOX1 promoter, one of the strongest eukaryotic promoters known. VTU’s approach delivers up to 20 g/L of secreted protein within a few weeks development time, and the company has a proven track record for expressing commercial levels of a wide range of proteins including serum proteins, cytokines, fusion proteins, Fabs, antibody derived fragments, scaffold proteins, and enzymes.

The protein target for this collaboration is DNA2.0’s IP-free CometGFP, which is part of a novel family of fluorescent and colorimetric proteins developed by DNA2.0. The corresponding IP-free genes are brought to market without expensive, constrained licensing.

“We developed our initial Pichia gene design algorithm with the world-leading P. pastoris laboratory of Anton Glieder, and we are thrilled to expand the breadth and scope of our P. pastoris technology for industrial scale applications with the proven commercial leader in the field, VTU Technology,” said Jeremy Minshull, Ph.D., cofounder and CEO of DNA2.0. “Controllable, consistent and strong protein expression is the goal regardless of the type of research in which you are engaged, and our patented GeneGPS technology has been proven to produce orders of magnitude increases in protein expression.”

Date: September 18, 2012
Source: DNA2.0


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50